BFRI ▼ -4.5% - Biofrontera Inc. $BFRI - Biofrontera has received FDA approval of Ameluz used in combination with the RhodoLED (SM Circulations) Biofrontera shares fell 4.5% today despite the company announcing FDA approval of Ameluz in combination with the RhodoLED illumination system, a potential expansion of the drug's approved uses in dermatology. The decline suggests investors may have been expecting stronger commercial impact from the regulatory clearance or had anticipated the approval already. 10-SEP-2026 11:31 AM ET